| Study |
Reference |
|
Ephross (Naratriptan versus Sumatriptan), 2014
|
Ephross SA Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry. Headache 2014;54:1158-72
|
|
Källén (control exposed to ergots), 2011
|
K?ll?n B Delivery outcome after maternal use of drugs for migraine: a register study in Sweden. Drug Saf 2011;34:691-703
|
|
Källén (control unexposed, disease free), 2011
|
K?ll?n B Delivery outcome after maternal use of drugs for migraine: a register study in Sweden. Drug Saf 2011;34:691-703
|
|
Spielmann (Control mainly exposed other treatments, sick), 2017
|
Spielmann K Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study. Cephalalgia 2017;:333102417724152
|
|
Spielmann (Control unexposed, disease free), 2017
|
Spielmann K Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study. Cephalalgia 2017;:333102417724152
|
|
Yusuf (Control exposed to Sumatriptan), 2018
|
Yusuf Use of existing electronic health care databases to evaluate medication safety in pregnancy: Triptan exposure in pregnancy as a case study. Pharmacoepidemiol Drug Saf 2018; 27:1309-1315
|
